首荟通便胶囊联合利那洛肽治疗便秘型肠易激综合征的临床观察

打开文本图片集

中图分类号 R969.4；R574.6 文献标志码A 文章编号1001-0408（2025）22-2828-05

DOI 10.6039/j.issn.1001-0408.2025.22.13

ABSTRACTOBJECTIVEToinvestigate theclinical eficacyandsafetyof Shouhui tongbiancapsulecombinedwithlinaclotide inthetreatmentofconstipation-predomiantiritablebowelsyndrome（IBS-C）.METHODSAtotalof97IBS-Cpatientsaditted to NanyangFirstPeople's HospitalbetweenMarch 2022 andFebruary2024wereenroled.Usingarandomnumbertablemethod， patients were divided into control group （ -n=46 ）and observation group（ n=51 ）. On the basis of routine treatment，the control groupwasgiven Linaclotidecapsulesoraly，whiletheobservationgroupreceivedLinaclotidecapsulescombinedwith Shouhui tongbiancapsuleorall.Thetreatmentcourseforboth groups was4weeks.Clinical effcacy，Iritable Bowel SyndromeSeverity Scale（IBS-SS），stoofrequency，BristolStoolFormScale（BSFS），IritableBowelSyndromeQualityofLifeQuestiaire （IBS-QOL）score，gastrointestinal hormone levels，anorectal manometryparameters，andtheoccrenceof adversereactios were compared betweethetwogroupsRESULTSTwopatientsinthecontrol groupandthreepatients intheobservationgroupdropped out due to adverse reactions. The effective rate in the observation group （ 87.50% ）was significantly higher than that in the control group（ 68.18% ） P<0.05 ）.Compared with pre-treatment，both groups showed significant increase in post-treatment stool frequency，BSFSscore，serumsubstanceP，andmotilinlevels.Conversely，IBS-SSscores，IBS-QOLscores，serumvasoactive intestinalpeptidelevels，nal-rectalpressediferencerectalcomplian，rectalsensationthreshold，anddefecationthesold were significantly reduced （ ⋅<0.05 ）. The observation group demonstrated superior outcomes to the control group （excluding rectal sensation and defecation thresholds， P<0.05 .No significant difference in theincidence ofadversereactionswasobserved between thetwo groups ⋅P>0.05 .CONCLUSIONS Comparedwithlinaclotidemonotherapy，Shouhuitongbiancapsulecombinedwithlinaclotideimprovesgastrointestinalhormone functionandnorectalanometryparametersin-Cpatiets，llviatesclincalsymptos，improvsqualityoflifedeibits favorablesafety.

KEYWORDS iritable bowel syndrome；constipation； Shouhui tongbian capsule； linaclotide；eficacy；safety

肠易激综合征（irritablebowelsyndrome，IBS）是一种以腹痛、腹胀或排便习惯改变且无明确器质性病变为主要特征的功能性肠病[。（剩余8639字）